The World Dispatch

A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

April 23, 2026

A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals Inc.’s DB-OTO, an AAV-mediated gene therapy. Branded Otarmeni (lunsotogene parvec), it is cleared specifically for hearing loss caused by variants in the otoferlin gene.

Source: bioworld

Publication

The World Dispatch

Source: World News API

Keywords: bioworld, fda, gene therapy, otoferlin gene, deals and m&a, aav, otof, policy, cnpv, otarmeni, commisioner’s national priority voucher, lunsotogene parvec, neurology/psychiatric, hearing loss, db-oto, regeneron pharmaceuticals inc., regulatory, ONLY AVAILABLE IN PROFESSIONAL AND CORPORATE PLANS